Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Summary

CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.

Timeline

Start

2022-01-07

Primary completion

2022-08-15

Completion

2023-01-28

Publications

• O'Hara DV, Bassi A, Wilcox A, Jha V, Rathore V, D'Cruz S, Snelling TL, Jones M, Totterdell J, Bangi A, Jain MK, Pollock C, Burrell L, Fox G, Jones C, Kotwal S, Faridah Syed Omar S, Jardine M; CLARITY 2.0 trial investigators. Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial. BMJ Open. 2024 Oct 22;14(10):e081790. doi: 10.1136/bmjopen-2023-081790.

Drugs

Indications